Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical OfficerSOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.
Sotera Health Appoints Christopher Simon to the Board of DirectorsCLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors.
Haemonetics Corp. (NYSE: HAE) Making Surprising Moves in Monday SessionHaemonetics Corporation (
NYSEHAE) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 4.85% on the day to $88.07.
How 2022's Biggest Healthcare Gainers Could Fare In 2023Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023
Watch for Continued Gains in Shares of Haemonetics Corporation (HAE)Shares of Haemonetics Corporation (
NYSEHAE) traded today at $78.81, eclipsing its 52-week high. Approximately 78,000 shares have changed hands today, as compared to an average 30-day volume of 426,000 shares.
